March 5, 2018 / 12:13 PM / 3 months ago

BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder

March 5 (Reuters) - Vanda Pharmaceuticals Inc:

* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY

* VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATED SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS IN NIGHTTIME AND DAYTIME SYMPTOMS OF JET LAG DISORDER​

* VANDA PHARMACEUTICALS - ‍RESULTS FROM JET8 STUDY SHOWED CLINICALLY MEANINGFUL EFFECTS OF HETLIOZ 20 MG ON PRIMARY ENDPOINT,MULTIPLE SECONDARY ENDPOINTS​

* VANDA PHARMACEUTICALS INC - ‍INTENDS TO SEEK MARKETING APPROVAL FOR USE OF HETLIOZ IN TREATMENT OF JET LAG DISORDER​

* VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATES IMPROVEMENT IN TOTAL SLEEP TIME BY 85 MINUTES VERSUS PLACEBO IN STUDY​

* VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATES IMPROVEMENT IN NEXT DAY ALERTNESS VERSUS PLACEBO IN STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below